Andreas Niethammer

Dr. Niethammer is the Chief Medical Officer of Aardvark Therapeutics, Inc.. Recently, he headed the Translational Medicine Team at Fate Therapeutics (Nasdaq: FATE) after serving as Chief Medical Officer of NantKwest, Inc. (Nasdaq: NK). He formerly held several executive positions, among others at Pfizer Inc and Lilly Pharmaceuticals. Dr. Niethammer is an inventor of several biomedical innovations in the field of Immunology and founded Vaximm AG in 2008 based on his inventions. Dr. Niethammer earned his M.D. degree and his board certification in Radiation Oncology from the University of Heidelberg, Germany. Dr. Niethammer received post-graduate training at the SCRIPPS Research Institute, La Jolla. He remains on the faculty in Heidelberg as Associate Professor.